Despite the recognized significance of APOE genotyping in assessing AD risk and patient stratification into APOE ε4+ and APOE ε4−, the intricate relationship involving APOE ε4 positivity, MMP-9, and TIMP-1 remains incompletely understood. This evidence concerns the gene MMP9 and Alzheimer disease.